CMS has provided 4 updates

Congratulations to Robin Motter-Mast, DO

Almost 99% of women diagnosed with breast cancer at the earliest stage live for 5 years or more.

Jeffrey Quinlan, MD, FAAFP, a family physician & academic leader, discusses the rising concerns about cannabis use during pregnancy, elaborating on the significance of preconception counseling, the risks associated with substance use during pregnancy, & advocates for open communication between physicians and patients.

September is Fetal Alcohol Spectrum Disorders (FASD) Awareness Month. This annual observance highlights the importance of talking about FASD, preventing FASD, and supporting families living with FASD.

Ahead of National Voter Registration Day on Sept. 17, AAFP has partnered with Vot-ER to provide a document that includes all compliance regarding HIPAA, HRSA guidance, IRS compliance, and the National Voter Registration Act.

During National Immunization Awareness Month, help increase your patients’ vaccination rates by recommending vaccines and how to access them.

The CY 2025 Medicare Physician Fee Schedule and Quality Payment Program proposed rule was released earlier this week. AAFP has issued a statement.

CMS identified phishing scams for medical records. This may include scammers faxing you fraudulent medical records requests to get you to send patient records in response.

83% of people with subjective cognitive decline have at least 1 chronic condition, which may make their condition more difficult to manage

Deadline: July 1, 2024

Medicare pays for opioid use disorder (OUD) screenings performed by physicians and non-physician practitioners.

Medicare pays for opioid use disorder (OUD) screenings performed by physicians and non-physician practitioners.

Tune in to updates to the Maryland Medicaid’s Preferred Drug List (PDL) and Brand Preferred over Generic Program, effective January 1, 2024.

Brand vs Generic (DAW6) Changes to Maryland Medicaid’s Preferred Drug List (PDL)

The training requirement is for prescribers of controlled substances in schedules II, III, IV, and V to complete a one-time, eight-hour training prior to their first registration or renewal of their DEA license.